Canopy Growth, Tilray Shares Rise After DOJ Proposes Marijuana Reclassification
By Josh Beckerman
Canopy Growth and Tilray Brands shares rose after the Justice Department submitted a proposed regulation to reschedule marijuana under the Controlled Substances Act.
Shares of Canopy Growth were up 17% to $11.60, while Tilray Brands shares were up 7.5% to $3.01 in recent trading.
The DOJ said the proposal emphasizes marijuana's "currently accepted medical use" in the U.S.
Shares of several cannabis companies increased in late April following an Associated Press report that said the U.S. Drug Enforcement Administration may reclassify marijuana to Schedule III from Schedule I.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
May 16, 2024 14:13 ET (18:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
What’s Happening In the Markets This Week
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase
-
After Earnings, Is Nio Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Lululemon Stock a Buy, a Sell, or Fairly Valued?